Abstract: A process is provided for inhibiting symptoms of food allergy or food intolerance in a subject that includes the oral adminstration to the subject suffering from food allergy or food intolerance an IgM. When administered in a therapeutic quantity based on the subject characteristics and the type of IgM, symptoms of food allergy or food intolerance in that subject are inhibited. Even non-secretory forms of IgM are effective when administered orally.

Abstract: Methods, systems, and computer-readable media for combined saving and validation are disclosed. A particular method includes receiving a command to save changes associated with a change set to a data storage device. Entities of the change set are validated and one or more pre-operation commands are executed on the change set. When a pre-operation command modifies one or more first entities of the change set, the first entities are revalidated. The method also includes executing a data operation based on the change set and executing one or more post-operation commands on the change set. When a post-operation command modifies one or more second entities of the change set, the second entities are re-validated.

Abstract: A fusion protein and process are provided by which double-stranded RNA containing small interfering RNA nucleotide sequences is introduced into specific cells and tissues. A cell surface receptor specific synthetic single chain variable domain (scFv) immunoglobulin fragment vehicle specific to a cell surface receptor of the cell and having a cell surface receptor specific binding site is provided. An RNA binding protein fused to said scFv is adsorbed with a double-stranded RNA or to a small hairpin RNA sequence complementary to a nucleotide sequence of a target gene in the cell and includes a small interfering RNA operative to suppress production of a target cellular protein. The scFv induces internalization into said cell of the fusion protein subsequent to the binding of said scFV to the cell surface receptor of the target cell.

Abstract: A process is provided for inhibiting symptoms of food allergy or food intolerance in a subject that includes the oral administration to the subject suffering from food allergy or food intolerance an IgA or an IgM. When administered in a therapeutic quantity based on the subject characteristics and the type of IgA or IgM, symptoms of food allergy or food intolerance in that subject are inhibited. Even non-secretory forms of IgA and IgM are effective when administered orally.

Abstract: A process for inhibiting symptoms of a subject with celiac disease is provided that includes administration of monoclonal-, or polyclonal-, monomeric, dimeric, or polymeric IgA. Joining secretory component to the IgA limits oral administration degradation. Formulating agents are mixed with the monomeric, dimeric, or polymeric IgA to yield a dosing form of a capsule, tablet, and a suppository. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating.

Abstract: A process is provided for inhibiting symptoms of food allergy or food intolerance in a subject that includes the oral adminstration to the subject suffering from food allergy or food intolerance an IgA or an IgM. When administered in a therapeutic quantity based on the subject characteristics and the type of IgA or IgM, symptoms of food allergy or food intolerance in that subject are inhibited. Even non-secretory forms of IgA and IgM are effective when administered orally.

Abstract: Methods, systems, and computer-readable media for combined saving and validation are disclosed. A particular method includes receiving a command to save changes associated with a change set to a data storage device. Entities of the change set are validated and one or more pre-operation commands are executed on the change set. When a pre-operation command modifies one or more first entities of the change set, the first entities are revalidated. The method also includes executing a data operation based on the change set and executing one or more post-operation commands on the change set. When a post-operation command modifies one or more second entities of the change set, the second entities are re-validated.

Abstract: A composition for treating a subject is provided. The composition includes antigen specific dimeric secretory IgA and pentameric IgM therapeutic. A process for manufacturing a medicament for the treatment of C. difficile associated disease in a human is also provided that the modification of antigen specific dimeric secretory IgA and pentameric IgM with secretory component to form a antigen specific dimeric secretory IgA and pentameric secretory IgM therapeutic. The antigen specific dimeric secretory IgA and the pentameric secretory IgM therapeutic is then mixed with formulating agents to create a capsule, tablet, liquid or suppository dosing form. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. A method of C. difficile treatment with the therapeutic is also provided that is amenable to supplementation with concurrent or prior antibiotic administration.

Abstract: A composition and method are provided by which double-stranded RNA containing small interfering RNA nucleotide sequences is introduced into specific cells and tissues for the purpose of inhibiting gene expression and protein production in those cells and tissues. Intracellular introduction of the small interfering RNA nucleotide sequences is accomplished by internalization of a target cell specific ligand to which the double-stranded RNA containing a small interfering RNA nucleotide sequence is conjugated. The ligand is specific to a unique target cell surface antigen. The ligand is either spontaneously internalized after binding to the cell surface antigen. Internalization is also facilitated by the binding of an RNA binding protein to the double-stranded RNA. If the unique cell surface antigen is not naturally internalized after binding to its ligand, internalization is promoted by the incorporation of a peptide into the structure of the ligand or attachment of such a peptide to the ligand.

Abstract: A composition and method are provided by which double-stranded RNA containing small interfering RNA nucleotide sequences is introduced into specific cells and tissues for the purpose of inhibiting gene expression and protein production in those cells and tissues. Intracellular introduction of the small interfering RNA nucleotide sequences is accomplished by the internalization of a target cell specific ligand bonded to a RNA binding protein to which a double-stranded RNA containing a small interfering RNA nucleotide sequence is adsorbed. The ligand is specific to a unique target cell surface antigen. The ligand is internalized after binding to the cell surface antigen or by the incorporation of a peptide into the structure of the ligand or RNA binding protein or attachment of such a peptide to the ligand or RNA binding protein. The composition and method are practiced in whole living mammals, as well as cells living in tissue culture.

Abstract: A composition for treating a subject is provided. The composition includes a pentameric secretory IgM therapeutic. Formulating agents are mixed with the pentameric secretory IgM to yield a dosing form of a capsule, tablet, and a suppository. A process for manufacturing a medicament for the treatment of C. difficile associated disease in a human is also provided that the modification of pentameric IgM with secretory component to form a pentameric secretory IgM therapeutic. The pentameric secretory IgM therapeutic is then mixed with formulating agents to create a capsule, tablet, or suppository dosing form. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. A method of C. difficile treatment with the therapeutic is also provided that is amenable to supplementation with concurrent or prior antibiotic administration.

Abstract: A composition for treating a subject is provided. The composition includes dimeric or polymeric secretory IgA therapeutic. Formulating agents are mixed with the dimeric or polymeric secretory IgA to yield a dosing form of a capsule, tablet, and a suppository. A process for manufacturing a medicament for the treatment of C. difficile associated disease in a human is also provided wherein dimeric or polymeric IgA is modified with secretory component to form a dimeric or polymeric secretory IgA therapeutic. The dimeric or polymeric secretory IgA therapeutic is then mixed with formulating agents to create a capsule, tablet, or suppository dosing form. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. A method of C. difficile treatment with the therapeutic is also provided that is amenable to supplementation with concurrent or prior antibiotic administration.

Abstract: A query web service wraps functionality of a number of database query subsystems. The query web service exposes interfaces with methods, when invoked, perform a wide variety of functions related to querying the database. Such methods allow a user to write to the interface to create, manage and execute queries against the entities in the database.

Abstract: A composition for treating a subject is provided. The composition includes antigen specific dimeric secretory IgA and pentameric IgM therapeutic. A process for manufacturing a medicament for the treatment of C. difficile associated disease in a human is also provided that the modification of antigen specific dimeric secretory IgA and pentameric IgM with secretory component to form a antigen specific dimeric secretory IgA and pentameric secretory IgM therapeutic. The antigen specific dimeric secretory IgA and the pentameric secretory IgM therapeutic is then mixed with formulating agents to create a capsule, tablet, liquid or suppository dosing form. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. A method of C. difficile treatment with the therapeutic is also provided that is amenable to supplementation with concurrent or prior antibiotic administration.

Abstract: A composition for treating a subject is provided. The composition includes dimeric or polymeric secretory IgM therapeutic. Formulating agents are mixed with the dimeric or polymeric secretory IgM to yield a dosing form of a capsule, tablet, and a suppository. A process for manufacturing a medicament for the treatment of C. difficile associated disease in a human is also provided that the modification of pentameric or hexameric IgM with secretory component to form a pentameric or hexameric secretory IgM therapeutic. The pentameric or hexameric secretory IgM therapeutic is then mixed with formulating agents to create a capsule, tablet, or suppository dosing form. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. A method of C. difficile treatment with the therapeutic is also provided that is amenable to supplementation with concurrent or prior antibiotic administration.

Abstract: A composition for treating a subject is provided. The composition includes dimeric or polymeric IgA therapeutic. Formulating agents are mixed with the dimeric or polymeric IgA to yield a dosing form of a capsule, tablet, and a suppository. A process for manufacturing a medicament for the treatment of C. difficile associated disease in a human is also provided that the sequential modification of monomeric IgA with J chain and secretory component to form a dimeric or polymeric IgA therapeutic. The dimeric or polymeric IgA therapeutic is then mixed with formulating agents to create a capsule, tablet, or suppository dosing form. The therapeutic is amenable to enrobement directly through microeneapsulation or the dosing form is coated with an enteric coating. A method of C. difficile treatment with the therapeutic is also provided that is amenable to supplementation with concurrent or prior antibiotic administration.

Abstract: A composition for treating a subject is provided. The composition includes dimeric or polymeric secretory IgA therapeutic. Formulating agents are mixed with the dimeric or polymeric secretory IgA to yield a dosing form of a capsule, tablet, and a suppository. A process for manufacturing a medicament for the treatment of C. difficile associated disease in a human is also provided that the modification of dimeric or polymeric IgA with secretory component to form a dimeric or polymeric secretory IgA therapeutic. The dimeric or polymeric secretory IgA therapeutic is then mixed with formulating agents to create a capsule, tablet, or suppository dosing form. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. A method of C. difficile treatment with the therapeutic is also provided that is amenable to supplementation with concurrent or prior antibiotic administration.

Abstract: Pooled human plasma is processed by cold ethanol fractionation to produce purified immunoglobulin G antibodies for intravenous administration. Immunoglobulin A is an unwanted by-product since intravenous administration of immunoglobulin A-containing immunoglobulin G can cause life-threatening anaphylaxis in some people. The present invention is the topical application of immunoglobulin A coupled with J chain, and optionally coupled with secretory component in order to render the immunoglobulin A more physiologically active, for the prevention or treatment of ocular diseases including ocular immune deficiency and infections. Antigen-specific monoclonal immunoglobulin A may be used.

Abstract: Pooled human plasma is processed by cold ethanol fractionation to produce purified immunoglobulin G antibodies for intravenous administration. Immunoglobulin A is an unwanted by-product since intravenous administration of immunoglobulin A-containing immunoglobulin G can cause life-threatening anaphylaxis in some people. The present invention is the aerosol administration, by metered dose inhaler or nebulizer, of by-product immunoglobulin A for the prevention or treatment of diseases including immunodeficiencies and infections. Antigen-specific monoclonal immunoglobulin A may be used. Immunoglobulin A from any of the aforementioned sources may then be coupled with recombinant J chain, and may then be additionally coupled with recombinant secretory component in order to render the immunoglobulin A more physiologically active. Immunoglobulin A, with or without J chain and secretory component, is then administered by aerosol inhalation.

Abstract: A query web service wraps functionality of a number of database query subsystems. The query web service exposes interfaces with methods, when invoked, perform a wide variety of functions related to querying the database. Such methods allow a user to write to the interface to create, manage and execute queries against the entities in the database.